Field evaluation of melatonin implants to advance the breeding season in 1-year-old farmed red deer hinds

The efficacy of controlled-release melatonin implants to advance the onset of the breeding season was assessed in 1-year-old red deer hinds on five commercial deer farms in various localities in the North Island of New Zealand. Between 44 and 60 hinds in each of six herds were equally divided among treatment and control groups at each site. Melatonin treatment commenced between 27 November and 16 December and was achieved by the subcutaneous administration of two 18 mg melatonin implants. Three doses were given at about 30 day intervals. Two adult stags for each hind group were treated with three 18 mg melatonin implants concurrently on either two or three occasions. On each property, treated and control hinds were joined as one herd to treated stags commencing 30 January-10 February and concluding 15 May-2 June. The hinds in the four experimental herds underwent rectal ultrasound examination May-June to estimate conception rate and foetal age. Calving dates, hind and calf mortalities, weaning weights, and the antler growth cycle and harvesting data were recorded. Overall, treatment with melatonin resulted in an average advance of the median calving date of 22 days (range 12-36 days) when compared with untreated controls in the same herds. Pregnancy rates were 91.3-100% in treated hinds and 63.6-100% in untreated hinds. There were no differences in calf mortality or calf sex ratio between treated and untreated groups. No hind deaths could be attributed to melatonin treatment. The weaning weights of calves were 5.68 kg and 4.43 kg heavier for the male and female offspring of treated hinds respectively, compared with those of control hinds. Treated stags commenced rutting behaviour earlier than normal and the antler casting and growth cycle was advanced. Treatment resulted in advancement of the seasonal pattern of coat changes in hinds and stags, but no untoward side effects of the melatonin treatments were observed.     

Adrenal adenoma in a cross-bred terrier

An adrenal tumour was diagnosed in a 12-year-old female cross-bred terrier. The dog was presented to the veterinary clinic because she had been gaining weight and had started urinating in the owners' house. Clinical findings included obesity, abdominal enlargement, thinning of the hair coat, seborrhoea sicca, and polydipsia and polyuria. The diagnosis was made by clinical pathology, endocrine function tests and abdominal radiography. Surgical removal of the neoplastic right adrenal gland resulted in resolution of the clinical signs, including regrowth of the hair coat.     

Guidelines for euthanasia of domestic animals by firearms

All animals that are to be killed, whether for food, for humane reasons, or because they are homeless, must receive a quick and painless death. In some smaller communities, veterinary or humane society expertise may not be readily available to humanely kill stray and unwanted animals. An alternative that provides for a humane death for the animal is by shooting. The following guidelines are intended to assist persons who must perform this usually distasteful task; they contain recommended techniques that will help to ensure that any animals killed by shooting will die in a humane way.     

Proposed criteria for classification of acute myeloid leukemia in dogs and cats

Blood and bone marrow smears from 49 dogs and cats, believed to have myeloproliferative disorders (MPD), were examined by a panel of 10 clinical pathologists to develop proposals for classification of acute myeloid leukemia (AML) in these species. French-American-British (FAB) group and National Cancer Institute (NCI) workshop definitions and criteria developed for classification of AML in humans were adapted. Major modifications entailed revision of definitions of blast cells as applied to the dog and cat, broadening the scope of leukemia classification, and making provisions for differentiating erythremic myelosis and undifferentiated MPD. A consensus cytomorphologic diagnosis was reached in 39 (79.6%) cases comprising 26 of AML, 10 of myelodysplastic syndrome (MDS), and 3 of acute lymphoblastic leukemia (ALL). Diagnostic concordance for these diseases varied from 60 to 81% (mean 73.3 +/- 7.1%) and interobserver agreement ranged from 51.3 to 84.6% (mean 73.1 +/- 9.3%). Various subtypes of AML identified included Ml, M2, M4, M5a, M5b, and M6. Acute undifferentiated leukemia (AUL) was recognized as a specific entity. M3 was not encountered, but this subclass was retained as a diagnostic possibility. The designations M6Er and MDS-Er were introduced where the suffix "Er" indicated preponderance of erythroid component. Chief hematologic abnormalities included circulating blast cells in 98% of the cases, with 36.7% cases having >30% blast cells, and thrombocytopenia and anemia in approximately 86 to 88% of the cases. Bone marrow examination revealed panmyeloid dysplastic changes, particularly variable numbers of megaloblastoid rubriblasts and rubricytes in all AML subtypes and increased numbers of eosinophils in MDS. Cytochemical patterns of neutrophilic markers were evident in most cases of Ml and M2, while monocytic markers were primarily seen in M5a and M5b cases. It is proposed that well-prepared, Romanowsky-stained blood and bone marrow smears should be examined to determine blast cell types and percentages for cytomorphologic diagnosis of AML. Carefully selected areas of stained films presenting adequate cellular details should be used to count a minimum of 200 cells. In cases with borderline diagnosis, at least 500 cells should be counted. The identity of blast cells should be ascertained using appropriate cytochemical markers of neutrophilic, monocytic, and megakaryocytic differentiation. A blast cell count of > 30% in blood and/or bone marrow indicates AML or AUL, while a count of < 30% blasts in bone marrow suggests MDS, chronic myeloid leukemias, or even a leukemoid reaction. Myeloblasts, monoblasts, and megakaryoblasts comprise the blast cell count. The FAB approach with additional criteria should be used to distinguish AUL and various subtypes of AML (Ml to M7 and M6Er) and to differentiate MDS, MDS-ER, chronic myeloid leukemias, and leukemoid reaction. Bone marrow core biopsy and electron microscopy may be required to confirm the specific diagnosis. Immunophenotyping with lineage specific antibodies is in its infancy in veterinary medicine. Development of this technique is encouraged to establish an undisputed identity of blast cells. Validity of the proposed criteria needs to be substantiated in large prospective and retrospective studies. Similarly, clinical relevance of cytomorphologic, cytochemical, and immunophenotypic characterizations of AML in dogs and cats remains to be determined.